Liver biopsy is currently the gold standard for staging

Size: px
Start display at page:

Download "Liver biopsy is currently the gold standard for staging"

Transcription

1 Diffusion-Weighted Magnetic Resonance Imaging for the Assessment of Fibrosis in Chronic Hepatitis C Maïté Lewin, 1,6 Armelle Poujol-Robert, 2 Pierre-Yves Boëlle, 3,6 Dominique Wendum, 4,6 Elisabeth Lasnier, 5 Magalie Viallon, 7 Jérôme Guéchot, 5 Christine Hoeffel, 1 Lionel Arrivé, 1,6 Jean-Michel Tubiana, 1,6 and Raoul Poupon 2,6 Liver biopsy is the gold standard for assessing fibrosis but has several limitations. We evaluated a noninvasive method, so-called diffusion-weighted magnetic resonance imaging (DWMRI), which measures the apparent diffusion coefficient (ADC) of water, for the diagnosis of liver fibrosis in patients with chronic hepatitis C virus (HCV). We analyzed 20 healthy volunteers and 54 patients with chronic HCV (METAVIR: F0, n 1; F1, n 30; F2, n 8; F3, n 5; and F4, n 10) prospectively included. Patients with moderate-to-severe fibrosis (F2-F3-F4) had hepatic ADC values lower than those without or with mild fibrosis (F0-F1; mean: versus mm 2 /s) and healthy volunteers (mean: mm 2 /s). In discriminating patients staged F3-F4, the areas under the receiving operating characteristic curves (AUCs) were 0.92 ( 0.04) for magnetic resonance imaging (MRI), 0.92 ( 0.05) for elastography, 0.79 ( 0.08) for FibroTest, 0.87 ( 0.06) for the aspartate aminotransferase to platelets ratio index (APRI), 0.86 ( 0.06) for the Forns index, and 0.87 ( 0.06) for hyaluronate. In these patients, the sensitivity, specificity, positive predictive value, and negative predictive value were 87%, 87%, 72%, and 94%, respectively, with an ADC cutoff level of mm 2 /s. In discriminating patients staged F2-F3-F4, the AUC values were 0.79 ( 0.07) for MRI, 0.87 ( 0.05) for elastography, 0.68 ( 0.09) for FibroTest, 0.81 ( 0.06) for APRI, 0.72 ( 0.08) for the Forns index, and 0.77 ( 0.06) for hyaluronate. Conclusion: This preliminary study suggests that DWMRI compares favorably with other noninvasive tests for the presence of significant liver fibrosis. (HEPATOLOGY 2007;46: ) Abbreviations: ADC, apparent diffusion coefficient; APRI, aspartate aminotransferase to platelets ratio index; AUC, area under the receiving operating characteristic curve; DWMRI, diffusion-weighted magnetic resonance imaging; f, FibroTest score; GGT, -glutamyl transpeptidase; HCV, hepatitis C virus; JT, Jonckheere-Terpstra; MR, magnetic resonance; MRI, magnetic resonance imaging; ROC, receiver operating characteristic; ROI, region of interest; SD, standard deviation; TE, echo time; TR, repetition time. From the 1 Department of Radiology, 2 Department of Hepatology, 3 Department of Public Health, 4 Department of Pathology, and 5 Department of Biochemistry, Saint-Antoine Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France; 6 Pierre et Marie Curie Paris 6 University, Paris, France; and 7 Siemens Medical Department, Saint Denis, France. Received November 19, 2006; accepted March 26, Address reprint requests to: Maïté Lewin, M.D., Ph.D., Service de Radiologie, Hôpital Saint Antoine, 184 Rue du Faubourg Saint Antoine, Paris, France. maite.lewin@sat.aphp.fr; fax: (33) Copyright 2007 by the American Association for the Study of Liver Diseases. Published online in Wiley InterScience ( DOI /hep Potential conflict of interest: Nothing to report. Liver biopsy is currently the gold standard for staging hepatic fibrosis. However, it is an invasive procedure with risks of complications. Furthermore, it has poor patient acceptance and shows possible interpretation and sampling errors. 1,2 Therefore, alternative noninvasive approaches have been developed to assess liver fibrosis in a wide range of chronic liver diseases, especially in patients with chronic hepatitis C virus (HCV) infection. These include routine biochemical and hematological tests, serum markers of connective tissue, and scoring systems using a combination of clinical and/or laboratory tests. 3-8 However, such methods fail to quantify liver fibrosis in about 50% of patients. 9 Other promising attempts in the assessment of liver fibrosis rely on imaging techniques. Recently, the measurement of liver stiffness with ultrasound transient elastography has been validated to detect significant fibrosis in patients with chronic hepatitis C. 10 However, transient elastography cannot be applied to patients with ascites, narrow intercostal spaces, and overweight status. In recent years, magnetic resonance imaging (MRI) techniques, including diffusionweighted magnetic resonance imaging (DWMRI), have been developed to characterize diseased tissue. DWMRI measures the apparent diffusion coefficient (ADC) of water, a parameter that is dependent on the tissue structure. Several reports on the measures of DWMRI in normal and cirrhotic livers suggest a lower ADC value in the 658

2 HEPATOLOGY, Vol. 46, No. 3, 2007 LEWIN ET AL. 659 latter, which is thought to reflect a restriction of water diffusion in fibrotic tissue. This prospective study was aimed at assessing the performance of DWMRI for the diagnosis of liver fibrosis in patients with chronic HCV infection with reference to other noninvasive methods: FibroTest, the aspartate aminotransferase to platelets ratio index (APRI), the Forns index, the serum hyaluronate concentration, and transient elastography. Patients and Methods Subjects. Twenty healthy adult volunteers with no evident hepatic pathology were recruited after oral informed consent. They consisted of 9 women and 11 men and had a mean age of years (range: years). Sixty consecutive patients were prospectively enrolled, but only 54 of these were eligible for a complete analysis because transient elastography was actually not carried out in 6 patients (because of organizational failure). The 54 patients included 37 men and 17 women with a mean age of years (range: years). The inclusion criteria were as follows: a chronic HCV infection defined by positive serum anti-hcv antibodies and detectable serum HCV RNA, the availability of a liver biopsy sample at least 10 mm long, the absence of clinical evidence for cirrhosis, and the oral informed consent of the patients. The exclusion criteria were as follows: a coinfection with human immunodeficiency virus or hepatitis B virus, other causes of liver diseases, hepatocellular carcinoma, and uninterpretable liver biopsy examination results. Our institutional review board approved the study. MRI Technique. MRI was performed before the liver biopsy examination, on the same day, with a 1.5-T superconducting magnetic resonance (MR) system (MAGNE- TOM Maestro Class Symphony, Siemens Medical Systems, Erlangen, Germany) with a 33 mt/m maximum gradient capability. A phased-array abdominal coil was made from a 6-element phase array settled on the anterior part of the patient and 4 elements of the spine coil integrated into the scanner table on the posterior part of the patient. Single-shot echoplanar diffusion-weighted imaging was synchronized with the patient respiration by means of the PACE (Prospective Acquisition Correction) navigator-triggered technique and was performed in all patients with 4 b values: 0, 200, 400, and 800 seconds/ mm 2. Parallel imaging (the GRAPPA [Generalized Autocalibrating Partially Parallel Acquisition] technique with an ipat [integrated Parallel Acquisition Techniques] factor of 2) was used to reduce both the susceptibility artifacts and acquisition time within the expiratory period. The signal acquisition time within the expiratory period did not exceed 1400 milliseconds (duration of the singleshot acquisition), and the total acquisition time depending on the respiratory period of the patient remained less than 2 minutes for all patients. A frequency-selective fat saturation was additionally applied to cancel chemical shift artifacts. The MR sequence parameters were as follows: a TR of 1400 milliseconds, a TE of 76 milliseconds, a matrix size, 3 excitations, a cm field of view, 11 slices with a 8-mm slice thickness, and a bandwidth of 1302 Hz/pixel. The diffusion gradients were applied in 3 orthogonal directions, and quantitative ADC maps were automatically calculated on a voxel-by-voxel basis with commercially available software (Syngo2004A, Siemens Medical Systems). The liver signal intensity was recorded as the mean of values generated by the placement of 3 separate circular regions of interest (ROIs) of a 0.5-cm diameter over the right hepatic lobe on the ADC mapping images in 5 different slices. Care was taken to exclude vessels from the ROIs. Transient Elastography. Measurements of liver stiffness by transient elastography were also performed before the liver biopsy examination, on the same day, with a FibroScan (Echosens, Paris, France) as previously described. 10 Ten validated measurements were performed on each patient. The success rate was calculated as the number of validated measurements divided by the total number of measurements. The results were expressed in kilopascals (kpa). The median value was considered representative of the elastic modulus of the liver. Only procedures with 10 validated measurements and a success rate of at least 60% were considered as reliable and were retained. Surrogate Serum Fibrosis Markers. The following parameters were determined for blood sampled on the day of liver biopsy: serum aspartate aminotransferase, alanine aminotransferase, -glutamyl transpeptidase (GGT), total bilirubin, platelet count, serum hyaluronate concentration, cholesterol, prothrombin index, a2-macroglobulin, apolipoprotein A1, and haptoglobin. Aspartate aminotransferase, alanine aminotransferase, GGT, and total bilirubin were assessed with an automated Olympus AU640 and were calibrated on a calibrator for automated systems (Roche Diagnostics). Apolipoprotein A1, alpha2- macroglobulin, and haptoglobin levels were determined with a BNII immunonephelemeter (Dade Behring, Marburg, Germany). Serum hyaluronate was assessed with an enzyme-linked protein-binding assay (hyaluronic acid test kit, Corgenix, Peterborough, United Kingdom). The APRI index was calculated as follows: aspartate aminotransferase ( upper limit of normal) 100/platelet count (10 9 /L). 5

3 660 LEWIN ET AL. HEPATOLOGY, September 2007 The Forns index was calculated according to the following formula: ln[(platelet count (10 9 /L)] ln[ggt (IU/L)] ln[age (years)] [cholesterol (mg/dl)]. 4 The laboratory followed the preanalytical and analytical recommendations required to obtain FibroTest results. 3 The transferability of the obtained results was validated for FibroTest calculations with BioPredictive Co. The FibroTest score (f) was calculated as follows: f log[ 2-macroglobulin (g/l)] log[haptoglobin (g/l)] log[ggt (IU/L)] [age (years)] log[bilirubin ( mol/ L)] [apolipoprotein A1 (g/l)] sex (female 0, male 1) Liver Histology and Quantification of Liver Fibrosis. Liver biopsy specimens were fixed in formalin and embedded in paraffin. All biopsy specimens were analyzed by an experienced pathologist blinded to the results of DWMRI, transient elastography, and blood tests. The mean size of the liver biopsy was 20.2 mm (range: mm), and 20 patients had liver biopsies larger than 25 mm. Liver fibrosis and necroinflammatory activity were evaluated semiquantitatively according to the METAVIR scoring system. Fibrosis was staged on a 0-4 scale as follows: F0 no fibrosis, F1 portal fibrosis without septa, F2 portal fibrosis and few septa, F3 numerous septa without cirrhosis, and F4 cirrhosis. The activity was graded as follows: A0 none, A1 mild, A2 moderate, and A3 severe. The presence of hepatic steatosis was also assessed and considered severe when greater than 30%. Statistical Analysis. Quantitative variables were compared with the Mann-Whitney test; trends were tested with the Jonckheere-Terpstra (JT) test. 14 The intrareader and extrareader variability for ADC determination were evaluated by the calculation of intraclass correlation coefficients. The coefficient of variation of the ADC values was calculated as the ratio of the standard error of the mean to the mean of the 15 ROIs studied in each individual. The diagnostic performance of DWMRI, transient elastography, FibroTest, APRI, the Forns index, the serum hyaluronate concentration, and their linear combinations was assessed with receiver operating characteristic (ROC) curves. An ROC curve is a plot of the sensitivity versus 1 specificity for all possible cutoff values. The most commonly used index of accuracy is the area under the receiving operating characteristic curve (AUC), with values close to 1.0 indicating high diagnostic accuracy. We also provided the standard deviation (SD) of the AUC as a precision index, using equivalence between the Wilcoxon statistic and the area under the curve. 15 Optimal Table 1. Characteristics of the 54 Patients During the Liver Biopsy Examination linear combinations of biomarkers were investigated for improving the diagnosis. 16 Optimal cutoff values for DWMRI were chosen to maximize the sum of the sensitivity and specificity, and the positive and negative predictive values were computed for these cutoff values. All statistical analyses were performed with the R software (cran.r-project.org). Results Characteristic n 54 Sex (men) 37 (60.6%) Age (years) Body mass index (kg/m 2 ) Histologic activity (METAVIR) A0-A1 28 (51.8%) A2 19 (35.2%) A3 7 (13%) Fibrosis score (METAVIR) F0 1 (1.85%) F1 30 (55.5%) F2 8 (14.8%) F3 5 (9.3%) F4 10 (18.5%) NOTE. The results are the means SD or n (%). Patients. The characteristics of our 54 patients with chronic HCV infection and fitting inclusion criteria are summarized in Table 1. The fibrosis grade distribution was as follows: F0, n 1; F1, n 30; F2, n 8; F3, n 5; and F4, n 10. Severe steatosis was found in 9 patients. Evaluation of Fibrosis by DWMRI and METAVIR Scores. In the volunteer group, the ADC values ranged from to mm 2 /s (mean: mm 2 /s). The mean coefficient of variation was 2.4%, with a 95% confidence interval of [ ]. The interreader and intrareader correlation coefficients were estimated to be 0.80 (range: ) and 0.75 (range: ), respectively. The ADC values of HCV patients ranged from 0.81 to mm 2 /s, with a mean individual coefficient of variation of 2.5% and a 95% confidence interval of [ ] (Fig. 1A). The ADC decreased as the fibrosis score increased (JT test, P ). Patients with moderate-to-severe fibrosis (F2- F3-F4) had hepatic ADC values lower than patients with or without mild fibrosis (F0-F1; mean: versus mm 2 /s, P ) and healthy volunteers (P ). Figure 2 shows the diagnostic value (ROC curves) of ADC values for stages F3-F4 (Fig. 2A) and for stages F2-F3-F4 (Fig. 2B). The

4 HEPATOLOGY, Vol. 46, No. 3, 2007 LEWIN ET AL. 661 Fig. 1. Box plots of (A) ADC values and (B) transient elastography values. The heavy line in each box represents the median. The error bars show the minimum and maximum values (range). Fig. 2. ROC curves for the ADC values, transient elastography, APRI, Forns index, and hyaluronate for the METAVIR fibrosis stages of (A) F3-F4 and (B) F2-F3-F4. corresponding AUCs are shown in Table 2. For an ADC value cutoff level of mm 2 /s for stages F3-F4, the sensitivity, specificity, positive predictive value, and negative predictive value were 87%, 87%, 72%, and 94% respectively. The ADC values decreased with the degree of necroinflammation (A0-A1, mm 2 /s, versus A2-A3, mm 2 /s, P 0.01). The difference in ADC according to the fibrosis score (F0-F1 versus F2-F3-F4) remained after standardization on the degree of necroinflammation (P 0.005), and there was no modification effect through inflammation between ADC and fibrosis (test for the interaction term: P 0.63). Images from patients with METAVIR score of F1 and F4 are shown in Fig. 3. Comparison of DWMRI with Transient Elastography and Serum Markers. Figure 1B shows box plots of transient elastography with values ranging from kpa. Transient elastography increased with increasing fibrosis score (JT test, P ). The AUC for stages F3-F4 (Fig. 2A) were 0.92 ( 0.04) for MRI, 0.92 ( 0.05) for elastography, 0.79 ( 0.08) for FibroTest, 0.87 ( 0.06) for APRI, 0.86 ( 0.06) for the Forns index, and 0.87 ( 0.06) for hyaluronate (Table 2). The AUC curve for stages F2-F3-F4 (Fig. 2B) were 0.79 ( 0.07) for MRI, 0.87 ( 0.05) for elastography, 0.68 ( 0.09) for FibroTest, 0.81 ( 0.06) for APRI, 0.72 ( 0.08) for the Forns index, and 0.77 ( 0.06) for hyal- Table 2. AUC and SD for the ADC Values, Transient Elastography, FibroTest, APRI, Forns Index, and Hyaluronate According to the METAVIR Fibrosis Stages for F3-F4 and F2-F3-F4 AUC METAVIR F3-F4 METAVIR F2-F3-F4 ADC (10 3 mm 2 /s) Transient elastography (kpa) FibroTest APRI Forns index Hyaluronate

5 662 LEWIN ET AL. HEPATOLOGY, September 2007 Fig. 3. Transverse diffusion-weighted MR images of livers showing the mapping ADC images for patients with METAVIR scores of (A) F1 and (B) F4. In part A, the representative ROI is shown by a white circle. uronate (Table 2). The AUC values were not statistically different between these noninvasive tests. Combinations of DWMRI, Transient Elastography, and Serum Markers. We evaluated linear combinations of ADC values, log(transient elastography), and APRI to improve the diagnosis of the fibrosis stage. The best diagnostic value was obtained with a combination of the ADC value and transient elastography [1.3 log(transient elastography) 2.3 ADC], which yielded only a slight improvement in the AUC: 0.88 ( 0.05) for stages F2-F3-F4. For discriminating F0-F1 versus F2-F3-F4, the best cut points were less than 1.24 for ADC and greater than 8.7 for transient elastography. DWMRI and transient elastography agreed on the diagnosis of F0-F1 versus F2- F3-F4 in 40 patients (74%). For the 14 patients about whom they disagreed, DWMRI agreed with liver specimen biopsy examination results in 8 cases (6 F0-F1 and 2 F2-F3-F4), and transient elastography agreed with liver examination results in 6 cases (3 F0-F1 and 3 F2-F3-F4). For the diagnosis of F 2, liver examination confirmed DWMRI in 43/54 cases (79.6%), transient elastography in 41/54 cases (76%), and concordant MRI elastography results in 32/40 cases (80%). For discriminating F0-F1-F2 versus F3-F4, the best cut points were less than 1.21 for ADC and greater than 12.9 for transient elastography. DWMRI and transient elastography agreed on the diagnosis of F0-F1-F2 versus F3-F4 in 44 patients (81.5%). For the 10 patients about whom they disagreed, DWMRI agreed with liver biopsy examination in 5 cases (4 F0-F1-F2 and 1 F3-F4), and transient elastography agreed with liver examination in 5 cases (4 F0-F1-F2 and 1 F3-F4). For the diagnosis of F 3, liver examination confirmed DWMRI in 47/54 cases (87%), transient elastography in 48/54 cases (89%), and concordant DWMRI elastography results in 41/44 cases (93%). Discussion We prospectively and blindly assessed the performance of DWMRI for the evaluation of the severity of liver fibrosis in patients with a chronic HCV infection. The diagnostic performance of DWMRI for liver fibrosis was found to be good and at least similar to that shown by transient elastography, APRI, the Forns index, FibroTest, and hyaluronate as reported in previous studies. The combination of ADC and transient elastography resulted in the best diagnostic performance for significant fibrosis (F 2). The development of noninvasive imaging methods such as DWMRI for the assessment of liver tissue damage represents a major advance in the management of liver diseases. Cross-sectional imaging findings of cirrhosis are generally capable of detecting advanced diseases on the basis of signs of portal hypertension with good sensitivity and specificity. 17 However, these findings have a limited usefulness for the detection of fibrosis. Diffusionweighted imaging, which is widely used in brain imaging for the evaluation of acute ischemic stroke, has become possible in the abdomen with the advent of the echoplanar MRI technique, which allows fast imaging times to be performed, thus minimizing the effect of gross physiologic motion from respiration and cardiac movement. 18,19 Diffusion is the motion of water molecules in biologic tissues, so-called Brownian motion, which is induced by heat. 12 Because in vivo random motions not only include water diffusion but also other random microscopic motions, such as microcirculation or perfusion in the capillary network, ADC, rather than the diffusion coefficient, is used to evaluate water diffusion. Collagen fiber is the main component of hepatic fibrosis. The protons contained in this tissue are less abundant than those in water and are tightly bound. Previous studies support

6 HEPATOLOGY, Vol. 46, No. 3, 2007 LEWIN ET AL. 663 the idea that ADC values are lower in a cirrhotic liver than in a normal liver However, an overlap has been reported between normal and cirrhotic livers. 12,19 To improve the signal intensity during DWMRI of the liver, we used a parallel imaging technique and combined multiple b values into a single acquisition, using diffusion gradients along 3 directions. This technical optimization of DW- MRI allowed us to have additional sample points for generating the isotropic diffusion and ADC maps with a subsequent improvement in the signal intensity. Actually, diffusion tensor imaging and parallel imaging could be used during DWMRI of the liver without compromising the measurement of hepatic ADC. 20 A few previous studies have addressed the question of ADC values in the liver. Differences in MR equipment and in echoplanar sequence parameters make it difficult to compare these studies with this one. In this respect, the choice of the b value plays a critical role. This value is a function of the amplitude and duration of the diffusion gradient and of the time allowed for the proton to diffuse between the 2 successive gradient pulses. Therefore, its choice is a compromise between adequate diffusion strength and image quality. According to the signal attenuation equation, S b S 0 exp( b ADC), only 2 measurements are in theory required to evaluate ADC: one in the absence of a diffusion gradient (S 0 ) and one in the presence of a diffusion gradient with a given b value (S b ). However, ADC evaluation is consolidated by the use of several b values, which allow a linear regression analysis to be performed from the derived equation, ln S b ln S 0 b ADC. 11,21,22 As far as a normal liver is concerned, our findings on volunteers (mean ADC value: mm 2 /s) are consistent with those reported by Taouli et al. 20 and Oner et al., 23 that is, and mm 2 /s, respectively, with b values of 0 and 500 seconds/mm 2. In a noncirrhotic liver, Müller et al. 24 reported mean ADC values of mm 2 /s, using 8 b values from seconds/mm 2, and Kim et al. 21 reported mean ADC values of mm 2 /s for b 100 seconds/mm 2, mm 2 /s for b 410 seconds/mm 2, and mm 2 /s for b 850 seconds/mm 2. In a cirrhotic liver, previous studies suggested ADC values lower than those in a normal liver. Müller et al. 24 reported ADC values of 0.9 and mm 2 /s (only 2 patients in the study), and Kim et al. 21 reported mean ADC values ranging from mm 2 /s for b 100 seconds/mm 2 to mm 2 /s for b 410 seconds/mm 2 to mm 2 /s for b 850 seconds/mm 2. Taouli et al. 12 reported mean ADC values of with b values of 0 and 400 seconds/mm 2 and mm 2 /s with b values of 0 and 500 seconds/mm 2. Aubé et al. 25 reported a mean value of mm 2 /s with b values of 0 and 200 seconds/mm 2. Only 2 previous studies attempted to evaluate ADC values in hepatic fibrosis. The first one, by Boulanger et al., 19 using 5 b values ranging from seconds/mm 2, reported a lack of a significant difference between the control subjects and HCV patients. The second one, by Koinuma et al., 13 using b values of 0 and 128 seconds/mm 2, found a correlation between the ADC values and fibrosis scores with mean ADC values of mm 2 /s in a normal liver, mm 2 /s in chronic hepatitis, and mm 2 /s in cirrhosis. However, both studies involved relatively small b values, an experimental condition under which ADC values are likely to be overestimated because the diffusion signal intensity is contaminated by perfusion. 21,22 Consistent with the study by Koinuma et al., 13 our results showed that the ADC values decreased as the fibrosis scores increased, and the difference between patients without or with mild fibrosis (F0-F1) and patients with significant fibrosis (F2-F3-F4) was statistically significant. Interestingly, the ADC values of the 6 patients with missing elastography data were consistent with this analysis: 3 F1 patients with a mean ADC value of mm 2 /s, 2 F2 patients with a mean ADC value of mm 2 /s, and 1 F3 patient with an ADC value of mm 2 /s. On the other hand, the fact that the mean ADC value was significantly higher in the volunteer group than that in the F2-F3-F4 patients may support a potential application of DWMRI as a detection tool. This point would deserve a specific study. We also found a significant relationship between the ADC values and necroinflammation scores. Besides fibrosis, it seems that ADC values might also reflect the intensity of inflammation or necrosis and decrease with the alteration of the tissue structure. On the other hand, steatosis could also affect the ADC value. However, only 9 of our patients had severe steatosis, and further studies are required to address this question. The disagreements sometimes found between the DWMRI and liver biopsy results for fibrosis assessment could be explained by biopsy sampling errors. As a matter of fact, Bedossa et al. 2 reported that fibrosis was correctly categorized in only 75% of 25-mm-long biopsy specimens and in only 65% of 15-mm-long biopsy specimens. In addition, the quantification of liver fibrosis using DWMRI provides an evaluation of the whole liver, enabling a more accurate assessment of disease severity in cases in which the fibrosis is not uniform across the entire organ.

7 664 LEWIN ET AL. HEPATOLOGY, September 2007 The diagnostic performance of DWMRI is at least similar to that of the other noninvasive tests. Interestingly, the combination of DWMRI with the other noninvasive tests results in a slight improvement of AUC values for stages F2-F3-F4. Compared with the diagnostic performances of transient elastography, FibroTest, APRI, the Forns index, and serum hyaluronate reported in the literature, the diagnostic performance of AUC values was at least similar. 3-5,26 Furthermore, the diagnostic performances of all noninvasive tests were better for patients with severe fibrosis (F 3) than for patients with significant fibrosis (F 2). In terms of practical care, one may prefer a method that is sensitive for F3-F4 patients because these must be offered treatment. While the issue is debated, F2 patients may also benefit and should therefore be detected. Figure 2 shows that DWMRI and transient elastography have much the same sensitivity and specificity characteristics for F0-F1-F2 classification versus F3-F4 classification, whereas DWMRI seems to be somewhat less sensitive than transient elastography with respect to F0-F1 classification versus F2-F3-F4 classification. However, these interpretations remain speculative because of the limited number of patients involved in the study. It is known that limitations of serum surrogate markers to determine the severity of fibrosis are acute inflammation, hemolysis, Gilbert syndrome, cholestasis, and renal failure. 3-5 Limitations of transient elastography should also be mentioned and concern obese patients and patients with ascites, even if clinically undetected. MRI also has classical contraindications (pacemakers and claustrophobia) but could be useful when other tools have failed. In addition, DWMRI benefits from the intrinsic advantages of MRI, such as the ability to perform conventional liver MRI at the same time to detect not only fibrosis but also hepatocellular carcinoma and signs of portal hypertension. In addition, DWMRI could potentially be used to follow treated liver fibrosis. However, the cost and availability of MRI are the main limitations of the technique. There is a combination of new imaging techniques to further improve the diagnostic efficacy of DWMRI. For example, proton spectroscopy at 1.5 T identifies various metabolites (choline and aliphatic hydrocarbons among others) that may be altered in both steatosis and fibrosis. 27 Perfusion MRI can detect the early alterations in the vascular architecture of fibrosis and cirrhosis. 28,29 Recently, the synergistic effects of gadolinium chelate and superparamagnetic iron oxide contrast agents in MRI for the hyperintense reticulation detection of fibrosis have achieved an accuracy greater than 90% for the diagnosis of fibrosis. 30,31 Another promising method is MR elastography, which measures the viscoelastic parameters of the liver according to the stage of fibrosis. 32,33 All these imaging-related technologies require further research to be incorporated into validated management algorithms. 34 In conclusion, the performance of DWMRI compares favorably with other noninvasive tests for the presence of significant liver fibrosis in patients with chronic hepatitis C infection. We suggest that DWMRI could be used as an adjunct to routine imaging to assess the degree of liver fibrosis in patients for whom liver MRI is performed. References 1. Cadranel JF, Rufat P, Degos F. Practices of liver biopsy in France: results of a prospective nationwide survey. HEPATOLOGY 2000;32: Bedossa P, Dargère D, Paradis V. Sampling variability of liver fibrosis in chronic hepatitis C. HEPATOLOGY 2003;38: Imbert-Bismut F, Ratziu V, Pieroni L, Charlotte F, Benhamou Y, Poynard T. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet 2001;357: Forns X, Ampurdanes S, Llovet JM, Aponte J, Quinto L, Martinez-Bauer E. Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model. HEPATOLOGY 2002;36: Wai CT, Greenson JK, Fontana RJ, Kalbfleisch JD, Marrero JA, Conjeevaram HS, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. HEPATOLOGY 2003;38: Patel K, Gordon SC, Jacobson I, Hézode C, Oh E, Smith KM, et al. Evaluation of a panel of non-invasive serum markers to differentiate mild from moderate-to-advanced liver fibrosis in chronic hepatitis C patients. J Hepatol 2004;41: Guéchot J, Laudat A, Loria A, Serfaty L, Poupon R, Giboudeau J. Diagnostic accuracy of hyaluronan and type III procollagen amino-terminal peptide serum assays as markers of liver fibrosis in chronic viral hepatitis C evaluated by ROC curve analysis. Clin Chem 1996;42: Adams LA, Bulsara M, Rossi E, DeBoer B, Speers D, George J, et al. Hepascore: an accurate validated predictor of liver fibrosis in chronic hepatitis C infection. Clin Chem 2005;51: Parkes J, Guha IN, Roderick P, Rosenberg W. Performance of serum marker panels for liver fibrosis in chronic hepatitis C. J Hepatol 2006;44: Ziol M, Handra-Luca A, Kettaneh A, Christidis C, Mal F, Kazemi F, et al. Non invasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C. HEPATOLOGY 2005;41: Ichikawa T, Haradome H, Hachiya J, Nitatori T, Araki T. Diffusionweighted MR imaging with a single-shot echoplanar sequence: detection and characterization of focal hepatic lesions. Am J Roentgenol 1998;170: Taouli B, Vilgrain V, Dumont E, Daire JL, Fan B, Menu Y. Evaluation of liver diffusion isotropy and characterization of focal hepatic lesions with two single-shot echo-planar MR imaging sequences: prospective study in 66 patients. Radiology 2003;226: Koinuma M, Ohashi I, Hanafusa K, Shibuya H. Apparent diffusion coefficient measurements with diffusion-weighted magnetic resonance imaging for evaluation of hepatic fibrosis. J Magn Reson Imaging 2005;22: Hollander M, Wolfe DA. Nonparametric Statistical Methods. 2nd ed. New York: Wiley; Hanley JA, McNeil B. The meaning and use of the area under a receiving operating characteristic (ROC) curve. Radiology 1982;143: Liu A, Schisterman EF, Zhu Y. On linear combinations of biomarkers to improve diagnostic accuracy. Stat Med 2005;24: Awaya H, Mitchell DG, Kamishima T, Holland G, Ito K, Matsumoto T. Cirrhosis: modified caudate-right lobe ratio. Radiology 2002;224:

8 HEPATOLOGY, Vol. 46, No. 3, 2007 LEWIN ET AL Cobbold J, Lim A, Wylezinska M, Cunningham C, Crossey M, Thomas H, et al. Magnetic resonance and ultrasound techniques for the evaluation of hepatic fibrosis. HEPATOLOGY 2006;43: Boulanger Y, Amara M, Lepanto L, Beaudoin G, Nguyen BN, Allaire G, et al. Diffusion-weighted MR imaging of the liver of hepatitis C patients. NMR Biomed 2003;16: Taouli B, Martin AJ, Qayyum A, Merriman RB, Vigneron D, Yeh BM, et al. Parallel imaging and diffusion tensor imaging for diffusion-weighted MRI of the liver: preliminary experience in healthy volunteers. Am J Roentgenol 2004;183: Kim T, Murakami T, Takahashi S, Hori M, Tsuda K, Nakamura H. Diffusion-weighted single-shot echoplanar MR imaging for liver disease. Am J Roentgenol 1999;173: Yamada I, Aung W, Himento Y, Nakagawa T, Shibuya H. Diffusion coefficients in abdominal organs and hepatic lesions: evaluation with intravoxel incoherent motion echo-planar MR imaging. Radiology 1999; 210: Oner AY, Celik H, Oktar SO, Tali T. Single breath-hold diffusionweighted MRI of the liver with parallel imaging: initial experience. Clin Radiol 2006;61: Müller MF, Prasad P, Siewert B, Nissenbaum MA, Raptopoulos V, Edelman RR. Abdominal diffusion mapping with use of a whole-body echoplanar system. Radiology 1994;190: Aubé C, Racineux PX, Lebigot J, Oberti F, Croquet V, Argaud C, et al. Diagnosis and quantification of hepatic fibrosis with diffusion weighted MR imaging: preliminary results. J Radiol 2004;85: Castéra L, Vergniol J, Foucher J, Le Bail B, Chanteloup E, Haaser M, et al. Prospective comparison of transient elastography, fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 2005;128: Cho SG, Kim MY, Kim HJ, Kim YS, Choi W, Shin SH, et al. Chronic hepatitis: in vivo proton MR spectroscopic evaluation of the liver and correlation with histopathologic findings. Radiology 2001;221: Materne R, Smith AM, Peeters F, Dehoux JP, Keyeux A, Horsmans Y, et al. Assessment of hepatic perfusion parameters with dynamic MRI. Magn Reson Med 2002;47: Annet L, Materne R, Danse E, Jamart J, Horsmans Y, Van Beers BE. Hepatic flow parameters measured with MR imaging and doppler US: correlations with degree of cirrhosis and portal hypertension. Radiology 2003;229: Aguirre DA, Behling CA, Alpert E, Hassanein TI, Sirlin CB. Liver fibrosis: noninvasive diagnosis with double contrast material-enhanced MR imaging. Radiology 2006;239: Lucidarme O, Baleston F, Cadi M, Bellin MF, Charlotte F, Ratziu V, et al. Non-invasive detection of liver fibrosis: is superparamagnetic iron oxide particle-enhanced MR imaging a contributive technique? Eur Radiol 2003;13: Huwart L, Peeters F, Sinkus R, Annet L, Salameh N, ter Beek LC, et al. Liver fibrosis: non-invasive assessment with MR elastography. MR Biomed 2006;19: Rouvière O, Yin M, Dresner MA, Rossman PJ, Burgart LJ, Fidler JL, et al. MR elastography of the liver: preliminary results. Radiology 2006;240: Naganawa S, Kawai H, Fukatsu H, Sakurai Y, Aoki I, Miura S, et al. Diffusion-weighted imaging of the liver: technical challenges and prospects for the future. Magn Reson Med Sci 2005;31:

*APHP: Hôpital Beaujon Professor P Bedossa, Dr F Degos, Professor P Marcellin, Professor

*APHP: Hôpital Beaujon Professor P Bedossa, Dr F Degos, Professor P Marcellin, Professor APPENDIX 1 LIST OF COINVESTIGATORS *APHP: Hôpital Beaujon Professor P Bedossa, Dr F Degos, Professor P Marcellin, Professor M Vidaud; Hôpital Cochin-Necker: Professor S Pol, Professor Ph Sogni, Professor

More information

Transient elastography is a new tool for assessing. Assessment of Biliary Fibrosis by Transient Elastography in Patients With PBC and PSC

Transient elastography is a new tool for assessing. Assessment of Biliary Fibrosis by Transient Elastography in Patients With PBC and PSC Assessment of Biliary Fibrosis by Transient Elastography in Patients With PBC and PSC Christophe Corpechot, 1 Ahmed El Naggar, 1 Armelle Poujol-Robert, 1 Marianne Ziol, 2 Dominique Wendum, 3 Olivier Chazouillères,

More information

ISMRM 2008 Handout-Clinical science for physicists and engineers course. Liver function and failure

ISMRM 2008 Handout-Clinical science for physicists and engineers course. Liver function and failure ISMRM 2008 Handout-Clinical science for physicists and engineers course 1 Liver function and failure Bachir Taouli, M.D. Assistant Professor, Department of Radiology New York University Medical Center

More information

Value of Diffusion-Weighted MRI for Assessing Liver Fibrosis and Cirrhosis

Value of Diffusion-Weighted MRI for Assessing Liver Fibrosis and Cirrhosis Gastrointestinal Imaging Original Research Sandrasegaran et al. DWI to Assess Liver Fibrosis and Cirrhosis Gastrointestinal Imaging Original Research Kumaresan Sandrasegaran 1 Fatih M. Akisik 1 Chen Lin

More information

Non-Invasive Testing for Liver Fibrosis

Non-Invasive Testing for Liver Fibrosis NORTHWEST AIDS EDUCATION AND TRAINING CENTER Non-Invasive Testing for Liver Fibrosis John Scott, MD, MSc Associate Professor, University of Washington Associate Clinic Director, Hep/Liver Clinic, Harborview

More information

Invasive. Sampling error. Interobserver variability. Nondynamic evaluation of

Invasive. Sampling error. Interobserver variability. Nondynamic evaluation of How to assess liver fibrosis Serum markers or FibroScan vs. liver biopsy? Laurent CASTERA & Pierre BEDOSSA Hôpital Beaujon, AP-HP, Clichy Université Paris-VII France 4 th Paris Hepatitis Conference, Paris,

More information

The role of non-invasivemethods in evaluating liver fibrosis of patients with non-alcoholic steatohepatitis

The role of non-invasivemethods in evaluating liver fibrosis of patients with non-alcoholic steatohepatitis The role of non-invasivemethods in evaluating liver fibrosis of patients with non-alcoholic steatohepatitis Objectives: Liver biopsy is the gold standard for diagnosing the extent of fibrosis in NAFLD/NASH;

More information

In Search of New Biomarkers for Nonalcoholic Fatty Liver Disease

In Search of New Biomarkers for Nonalcoholic Fatty Liver Disease REVIEW In Search of New Biomarkers for Nonalcoholic Fatty Liver Disease Ting-Ting Chan, M.R.C.P., and Vincent Wai-Sun Wong, M.D. Nonalcoholic fatty liver disease (NAFLD) affects 15% to 40% of the general

More information

Transient elastography in chronic viral liver diseases

Transient elastography in chronic viral liver diseases 4 th AISF POST-MEETING COURSE Roma, 26 Febbraio 2011 Transient elastography in chronic viral liver diseases CRISTINA RIGAMONTI, M.D., Ph.D. Transient elastography (TE): a rapid, non-invasive technique

More information

Noninvasive Techniques for the Evaluation and Monitoring of Patients With Chronic Liver Disease

Noninvasive Techniques for the Evaluation and Monitoring of Patients With Chronic Liver Disease Noninvasive Techniques for the Evaluation and Monitoring of Patients With Chronic Liver Disease Policy Number: 2.04.41 Last Review: 2/2019 Origination: 2/2017 Next Review: 2/2020 Policy Blue Cross and

More information

Diffusion weighted MRI in evaluation of transplanted kidney: Preliminary clinical experience

Diffusion weighted MRI in evaluation of transplanted kidney: Preliminary clinical experience African Journal of Nephrology (2009) 13: 26-30 Original Article AJN Diffusion weighted MRI in evaluation of transplanted kidney: Preliminary clinical experience Mohamed Abou El-Ghar; M.D, Huda Refaie;

More information

DIAGNOSIS OF CIRRHOSIS BY TRANSIENT ELASTOGRAPHY (FIBROSCAN ): A PROSPECTIVE STUDY.

DIAGNOSIS OF CIRRHOSIS BY TRANSIENT ELASTOGRAPHY (FIBROSCAN ): A PROSPECTIVE STUDY. Gut Online First, published on July 14, 2005 as 10.1136/gut.2005.069153 DIAGNOSIS OF CIRRHOSIS BY TRANSIENT ELASTOGRAPHY (FIBROSCAN ): A PROSPECTIVE STUDY. Juliette Foucher (1), Elise Chanteloup (1), Julien

More information

Noninvasive Diagnosis and Staging of Liver Disease. Naveen Gara, MD

Noninvasive Diagnosis and Staging of Liver Disease. Naveen Gara, MD Noninvasive Diagnosis and Staging of Liver Disease Naveen Gara, MD Outline Brief overview of the anatomy of liver Liver-related lab tests Chronic liver disease progression Estimation of liver fibrosis

More information

Noninvasive Techniques for the Evaluation and Monitoring of Patients With Chronic Liver Disease

Noninvasive Techniques for the Evaluation and Monitoring of Patients With Chronic Liver Disease Noninvasive Techniques for the Evaluation and Monitoring of Patients With Chronic Liver Disease Policy Number: 2.04.41 Last Review: 2/2018 Origination: 2/2017 Next Review: 2/2019 Policy Blue Cross and

More information

Non-Invasive Assessment of Liver Fibrosis. Patricia Slev, PhD University of Utah Department of Pathology

Non-Invasive Assessment of Liver Fibrosis. Patricia Slev, PhD University of Utah Department of Pathology Non-Invasive Assessment of Liver Fibrosis Patricia Slev, PhD University of Utah Department of Pathology Disclosure Patricia Slev has no relevant financial relationships to disclose. 2 Chronic Liver Disease

More information

MP Noninvasive Techniques for the Evaluation and Monitoring of Patients With Chronic Liver Disease

MP Noninvasive Techniques for the Evaluation and Monitoring of Patients With Chronic Liver Disease Medical Policy BCBSA Ref. Policy: 2.04.41 Last Review: 11/15/2018 Effective Date: 11/15/2018 Section: Medicine Related Policies 9.01.502 Experimental / Investigational Services DISCLAIMER Our medical policies

More information

When to Treat: Staging Liver Disease David L. Thomas, MD, MPH

When to Treat: Staging Liver Disease David L. Thomas, MD, MPH When to Treat: Staging Liver Disease David L. Thomas, MD, MPH Professor of Medicine Johns Hopkins School of Medicine Disclosures Received royalties from UpToDate, Inc. Staging refers to the assessment

More information

PROPOSTA DI UN NUOVO ALGORIMO PER LA DIAGNOSI ECOGRAFICA DELLE MALATTIE CRONICHE DEL FEGATO

PROPOSTA DI UN NUOVO ALGORIMO PER LA DIAGNOSI ECOGRAFICA DELLE MALATTIE CRONICHE DEL FEGATO PROPOSTA DI UN NUOVO ALGORIMO PER LA DIAGNOSI ECOGRAFICA DELLE MALATTIE CRONICHE DEL FEGATO A. Giorgio Direttore del servizio di Ecografia Interventistica Istituto Clinico S.Rita -IRCCS -Atripalda (Avellino)

More information

The role of ARFI and APRI in diagnosis of liver fibrosis on patients with common chronic liver diseases

The role of ARFI and APRI in diagnosis of liver fibrosis on patients with common chronic liver diseases RESEARCH ARTICLE The role of ARFI and APRI in diagnosis of liver fibrosis on patients with common chronic liver diseases Objective: This study aimed to investigate the value of liver fibrosis assessment

More information

Abstract INTRODUCTION RAPID COMMUNICATION

Abstract INTRODUCTION RAPID COMMUNICATION Online Submissions: wjg.wjgnet.com World J Gastroenterol 2008 December 14; 14(46): 7117-7121 wjg@wjgnet.com World Journal of Gastroenterology ISSN 1007-9327 doi:10.3748/wjg.14.7117 2008 The WJG Press.

More information

INHSU th International Symposium on Hepatitis Care In Substance Users

INHSU th International Symposium on Hepatitis Care In Substance Users INHSU 2015 4 th International Symposium on Hepatitis Care In Substance Users Sydney, 7 October 2015 Non-invasive liver fibrosis assessment: Opportunities for enhanced liver disease assessment and treatment

More information

Non invasive assessment of liver fi brosis ONLY. liver diseases liver biopsy liver fibrosis biomarkers fibrotest fibroscan

Non invasive assessment of liver fi brosis ONLY. liver diseases liver biopsy liver fibrosis biomarkers fibrotest fibroscan Ann Transplant, 2008; 13(2): 5-11 Received: 2008.04.15 Accepted: 2008.04.29 Published: 2008.06.17 Key words Full-text PDF: Word count: 1979 Tables: 1 Figures: 2 References: 50 Author s address: Non invasive

More information

NONINVASIVE IMAGING METHODS FOR ASSESSMENT OF LIVER DAMAGE IN NASH

NONINVASIVE IMAGING METHODS FOR ASSESSMENT OF LIVER DAMAGE IN NASH NONINVASIVE IMAGING METHODS FOR ASSESSMENT OF LIVER DAMAGE IN NASH Bachir Taouli, MD Director of Body MRI and Cancer Imaging Program Department of Radiology / Translational and Molecular Imaging Institute

More information

Alternatives to Liver Biopsy for Assessing Liver Disease

Alternatives to Liver Biopsy for Assessing Liver Disease Alternatives to Liver Biopsy for Assessing Liver Disease a report by Thierry Poynard Professor of Medicine, University of Paris The consensus conference statements recommend liver biopsy in the management

More information

DIFFUSION-WEIGHTED MAGNETIC RESONANCE IMAGING OF THE LIVER IN HEPATITIS B PATIENTS

DIFFUSION-WEIGHTED MAGNETIC RESONANCE IMAGING OF THE LIVER IN HEPATITIS B PATIENTS DIFFUSIO-WEIGHTED MAGETIC RESOACE IMAGIG OF THE LIVER I HEATITIS B ATIETS WITH CHILD-UGH A CIRRHOSIS Feng-O Hsu, 1 Yen-Yu Chiou, 1 Chiao-Yun Chen, 1,2 Gin-Chung Liu, 1,2 Hui-Chen Chu, 3 Hui-Cheng Liu,

More information

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

Medical Policy An independent licensee of the Blue Cross Blue Shield Association Noninvasive Techniques for the Evaluation and Page 1 of 34 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Noninvasive Techniques for the Evaluation and Professional

More information

The evaluation of liver fibrosis is a key step to manage

The evaluation of liver fibrosis is a key step to manage GASTROENTEROLOGY 2011;140:1970 1979 CLINICAL LIVER, BILIARY TRACT Noninvasive Tests for Fibrosis and Liver Stiffness Predict 5-Year Outcomes of Patients With Chronic Hepatitis C JULIEN VERGNIOL,* JULIETTE

More information

National Horizon Scanning Centre. Enhanced Liver Fibrosis Test (ELF) for evaluating liver fibrosis. June 2008

National Horizon Scanning Centre. Enhanced Liver Fibrosis Test (ELF) for evaluating liver fibrosis. June 2008 Enhanced Liver Fibrosis Test (ELF) for evaluating liver fibrosis June 2008 This technology summary is based on information available at the time of research and a limited literature search. It is not intended

More information

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

Medical Policy An independent licensee of the Blue Cross Blue Shield Association Noninvasive Techniques for the Evaluation and Monitoring of Page 1 of 38 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Noninvasive Techniques for the Evaluation

More information

Influence of cardiac motion on diffusion-weighted magnetic resonance imaging of the liver

Influence of cardiac motion on diffusion-weighted magnetic resonance imaging of the liver Magn Reson Mater Phy (2009) 22:319 325 DOI 10.1007/s10334-009-0183-1 RESEARCH ARTICLE Influence of cardiac motion on diffusion-weighted magnetic resonance imaging of the liver Thomas C. Kwee Taro Takahara

More information

Patients and Methods. study was conducted according to the Declaration of Helsinki.

Patients and Methods. study was conducted according to the Declaration of Helsinki. SAFE Biopsy: A Validated Method for Large-Scale Staging of Liver Fibrosis in Chronic Hepatitis C Giada Sebastiani, 1 Philippe Halfon, 2 Laurent Castera, 3 Stanislas Pol, 4 David L. Thomas, 5 Alessandra

More information

Liver 102: Injury and Healing

Liver 102: Injury and Healing Liver 102: Injury and Healing Dawn Pease, MSN, RN, ANP-BC Brackenridge Specialty Clinics University Medical Center Brackenridge Austin, TX Seton Healthcare Family Liver 102 Outline Biochemical patterns

More information

MR Elastography of Liver

MR Elastography of Liver MR Elastography of Liver Sudhakar K. Venkatesh, MD, FRCR Professor of Radiology Mayo Clinic College of Medicine Consultant, Abdominal Division Radiology, Mayo Clinic Rochester, MN, USA 19 th May 2018 2018

More information

Section: Laboratory Last Reviewed Date: June Policy No: 47 Effective Date: August 1, 2013

Section: Laboratory Last Reviewed Date: June Policy No: 47 Effective Date: August 1, 2013 Medical Policy Manual Topic: Multianalyte Assays with Algorithmic Analysis for the Evaluation and Monitoring of Patients with Chronic Liver Disease Date of Origin: June 2013 Section: Laboratory Last Reviewed

More information

Module 1 Introduction of hepatitis

Module 1 Introduction of hepatitis Module 1 Introduction of hepatitis 1 Training Objectives At the end of the module, trainees will be able to ; Demonstrate improved knowledge of the global epidemiology of the viral hepatitis Understand

More information

Transient elastography the state of the art

Transient elastography the state of the art Transient elastography the state of the art Laurent CASTERA, MD PhD Department of Hepatology, Hôpital Beaujon, Clichy Université Paris-7, France White Nights of Hepatology, St Petersburg, Russia, june

More information

New Tools for Assessing Disease Sererity, progression and regression in HBV and HCV

New Tools for Assessing Disease Sererity, progression and regression in HBV and HCV New Tools for Assessing Disease Sererity, progression and regression in HBV and HCV Jidong Jia, MD, PhD Beijing Friendship Hospital, Capital Medical University 2016-3-14 Disclosure Consultation for Abbvie

More information

Medical Review Approaches to the Diagnosis of Liver Fibrosis

Medical Review Approaches to the Diagnosis of Liver Fibrosis Medical Review Approaches to the Diagnosis of Liver Fibrosis Hiroko Iijima Department of Hepatobiliary and Pancreatic Disease Ultrasound Imaging Center, Hyogo College of Medicine Hiroko Iijima Department

More information

NONINVASIVE TECHNIQUES FOR EVALUATION AND MONITORING OF CHRONIC LIVER DISEASE

NONINVASIVE TECHNIQUES FOR EVALUATION AND MONITORING OF CHRONIC LIVER DISEASE LIVER DISEASE Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices and drugs are

More information

iu22 Liver Shear Wave ElastPQ

iu22 Liver Shear Wave ElastPQ iu22 Liver Shear Wave ElastPQ Clinical Case Study Lucy Wang Clinical Application Specialist ASEAN Case Study: History: 58-year-old male patient, hepatitis B virus (HBV) carrier, with non clinical symptoms

More information

HEPATIC ELASTOGRAPHY AND FIB-4 SCORE VERSUS LIVER BIOPSY FOR ASSESSMENT OF LIVER FIBROSIS IN CHRONIC HCV PATIENTS

HEPATIC ELASTOGRAPHY AND FIB-4 SCORE VERSUS LIVER BIOPSY FOR ASSESSMENT OF LIVER FIBROSIS IN CHRONIC HCV PATIENTS HEPATIC ELASTOGRAPHY AND FIB-4 SCORE VERSUS LIVER BIOPSY FOR ASSESSMENT OF LIVER FIBROSIS IN CHRONIC HCV PATIENTS Essam A. Wahab*, Talaat Fathy** Sameh Saber*** and Hanan S. Ahmad**** Internal Medicine*,

More information

Prise en charge actuelle de l'hépatite C et nouvelles approches thérapeutiques

Prise en charge actuelle de l'hépatite C et nouvelles approches thérapeutiques Prise en charge actuelle de l'hépatite C et nouvelles approches thérapeutiques Future Complications of Darius Moradpour Service de Gastro-entérologie et d'hépatologie Centre Hospitalier Universitaire Vaudois

More information

Original article On-treatment monitoring of liver fibrosis with transient elastography in chronic hepatitis B patients

Original article On-treatment monitoring of liver fibrosis with transient elastography in chronic hepatitis B patients Antiviral Therapy 2011; 16:165 172 (doi: 10.3851/IMP1726) Original article On-treatment monitoring of liver fibrosis with transient elastography in chronic hepatitis B patients Grace Lai-Hung Wong 1,2,

More information

Aspartate Aminotransferase-to-Platelet Ratio Index for Fibrosis and Cirrhosis Prediction in Chronic Hepatitis C Patients

Aspartate Aminotransferase-to-Platelet Ratio Index for Fibrosis and Cirrhosis Prediction in Chronic Hepatitis C Patients BJID 2008; 12 (February) 15 Aspartate Aminotransferase-to-Platelet Ratio Index for Fibrosis and Cirrhosis Prediction in Chronic Hepatitis C Patients Roberto Gomes da Silva Junior 1, Ricardo Fakhouri 2,

More information

Acoustic radiation force imaging sonoelastography for noninvasive staging of liver fibrosis

Acoustic radiation force imaging sonoelastography for noninvasive staging of liver fibrosis Online Submissions: wjg.wjgnet.com World J Gastroenterol 2009 November 28; 15(44): 5525-5532 wjg@wjgnet.com World Journal of Gastroenterology ISSN 1007-9327 doi:10.3748/wjg.15.5525 2009 The WJG Press and

More information

NON INVASIVE ASSESSMENT OF LIVER FIBROSIS : FIBROSCAN

NON INVASIVE ASSESSMENT OF LIVER FIBROSIS : FIBROSCAN NON INVASIVE ASSESSMENT OF LIVER FIBROSIS : FIBROSCAN M. Beaugrand Service d Hépatologied Hopital J. Verdier BONDY 93143 et Université Paris XIII MAINZ 21.09.2008 ASSESSMENT OF FIBROSIS : WHY? Management

More information

Magnetization-tagged MRI is a simple method for predicting liver fibrosis

Magnetization-tagged MRI is a simple method for predicting liver fibrosis pissn 2287-2728 eissn 2287-285X Original Article Clinical and Molecular Hepatology 2016;22:140-145 Magnetization-tagged MRI is a simple method for predicting liver fibrosis Kyung-Eun Kim 1, Mi-Suk Park

More information

Preliminary clinical experience with Shear Wave Dispersion Imaging for liver viscosity

Preliminary clinical experience with Shear Wave Dispersion Imaging for liver viscosity Preliminary clinical experience with Shear Wave Dispersion Imaging for liver viscosity Dr. Katsutoshi Sugimoto Department of Gastroenterology and Hepatology, Tokyo Medical University, Japan Introduction

More information

Liver Fat Quantification

Liver Fat Quantification Liver Fat Quantification Jie Deng, PhD, DABMP Department of Medical Imaging May 18 th, 2017 Disclosure Research agreement with Siemens Medical Solutions 2 Background Non-alcoholic fatty liver diseases

More information

Improved Hepatic Fibrosis Grading Using Point Shear Wave Elastography and Machine Learning

Improved Hepatic Fibrosis Grading Using Point Shear Wave Elastography and Machine Learning Improved Hepatic Fibrosis Grading Using Point Shear Wave Elastography and Machine Learning Presenter: Hersh Sagreiya 1, M.D. Authors: Alireza Akhbardeh 1, Ph.D., Isabelle Durot 1, M.D., Carlo Filice 2,

More information

Non-invasive diagnosis of hepatitis B virus-related cirrhosis

Non-invasive diagnosis of hepatitis B virus-related cirrhosis Online Submissions: http://www.wjgnet.com/esps/ bpgoffice@wjgnet.com doi:10.3748/wjg.v20.i2.445 World J Gastroenterol 2014 January 14; 20(2): 445-459 ISSN 1007-9327 (print) ISSN 2219-2840 (online) 2014

More information

Real-time elastography as a noninvasive assessment of liver fibrosis in chronic hepatitis C Egyptian patients: a prospective study

Real-time elastography as a noninvasive assessment of liver fibrosis in chronic hepatitis C Egyptian patients: a prospective study ORIGINAL ARTICLE Annals of Gastroenterology (2016) 29, 1-5 Real-time elastography as a noninvasive assessment of liver fibrosis in chronic hepatitis C Egyptian patients: a prospective study Lamiaa Mobarak

More information

Follow-up of patients with SVR Lawrence Serfaty Service d Hépatologie, UMR_S 938 Hôpital Saint-Antoine Université Pierre&Marie Curie Paris, France

Follow-up of patients with SVR Lawrence Serfaty Service d Hépatologie, UMR_S 938 Hôpital Saint-Antoine Université Pierre&Marie Curie Paris, France 9th Paris Hepatitis Conference, January 11-12, 2016 Follow-up of patients with SVR Lawrence Serfaty Service d Hépatologie, UMR_S 938 Hôpital Saint-Antoine Université Pierre&Marie Curie Paris, France Disclosures

More information

Chronic infection with the hepatitis C virus. Comparison and Validation of Simple Noninvasive Tests for Prediction of Fibrosis in Chronic Hepatitis C

Chronic infection with the hepatitis C virus. Comparison and Validation of Simple Noninvasive Tests for Prediction of Fibrosis in Chronic Hepatitis C Comparison and Validation of Simple Noninvasive Tests for Prediction of Fibrosis in Chronic Hepatitis C Carolin Lackner, 1 Gerd Struber, 1 Bernadette Liegl, 1 Sebastian Leibl, 1 Petra Ofner, 2 Csilla Bankuti,

More information

Noninvasive markers of liver fibrosis in Latin America and Mexico.

Noninvasive markers of liver fibrosis in Latin America and Mexico. Noninvasive markers of liver fibrosis in Latin America and Mexico. MODULE V Vol. 9 Suppl.1, 2010: S43-S48 S43 Noninvasive markers of liver fibrosis in Latin America and Mexico Misael Uribe,*, ** Ylse Gutiérrez-Grobe,*

More information

Effect of intravenous contrast medium administration on prostate diffusion-weighted imaging

Effect of intravenous contrast medium administration on prostate diffusion-weighted imaging Effect of intravenous contrast medium administration on prostate diffusion-weighted imaging Poster No.: C-1766 Congress: ECR 2015 Type: Authors: Keywords: DOI: Scientific Exhibit J. Bae, C. K. Kim, S.

More information

Evaluation of Fibrosis Progression by Noninvasive Biochemical Markers in Egyptian Patients with Chronic Hepatitis B

Evaluation of Fibrosis Progression by Noninvasive Biochemical Markers in Egyptian Patients with Chronic Hepatitis B EJOHG 10.5005/jp-journals-10018-1016 Evaluation of Fibrosis Progression by Noninvasive Biochemical Markers in Egyptian Patients with Chronic Hepatitis B ORIGINAL ARTICLE Evaluation of Fibrosis Progression

More information

Xiao-Ling Chi, Mei-Jie Shi, Huan-Ming Xiao, Yu-Bao Xie, and Gao-Shu Cai. Correspondence should be addressed to Xiao-Ling Chi;

Xiao-Ling Chi, Mei-Jie Shi, Huan-Ming Xiao, Yu-Bao Xie, and Gao-Shu Cai. Correspondence should be addressed to Xiao-Ling Chi; Evidence-Based Complementary and Alternative Medicine Volume 2016, Article ID 3743427, 6 pages http://dx.doi.org/10.1155/2016/3743427 Research Article The Score Model Containing Chinese Medicine Syndrome

More information

The Egyptian Journal of Hospital Medicine (July 2018) Vol. 72 (11), Page

The Egyptian Journal of Hospital Medicine (July 2018) Vol. 72 (11), Page The Egyptian Journal of Hospital Medicine (July 2018) Vol. 72 (11), Page 5547-5551 The Role of Dynamic MRI with Diffusion Weighted Images in Evaluation of Portal Vein Thrombosis in Hepatic Patients 1 Suzan

More information

Evaluation and Staging of Liver Fibrosis

Evaluation and Staging of Liver Fibrosis Hepatitis C Online PDF created October 31, 2018, 2:08 pm Evaluation and Staging of Liver Fibrosis This is a PDF version of the following document: Section 2: Evaluation, Staging, and Monitoring of Chronic

More information

Hepascore: An Accurate Validated Predictor of Liver Fibrosis in Chronic Hepatitis C Infection

Hepascore: An Accurate Validated Predictor of Liver Fibrosis in Chronic Hepatitis C Infection Papers in Press. First published July 28, 2005 as doi:10.1373/clinchem.2005.048389 Clinical Chemistry 51:10 000 000 (2005) General Clinical Chemistry Hepascore: An Accurate Validated Predictor of Liver

More information

Noninvasive Evaluation of Liver Fibrosis Using Real-time Tissue Elastography and Transient Elastography (FibroScan)

Noninvasive Evaluation of Liver Fibrosis Using Real-time Tissue Elastography and Transient Elastography (FibroScan) ORIGINAL RESEARCH Noninvasive Evaluation of Liver Fibrosis Using Real-time Tissue Elastography and Transient Elastography (FibroScan) Fankun Meng, MD, Ying Zheng, MD, Qi Zhang, MD, Xiaojie Mu, MD, Xiaoluan

More information

Usefulness of Non-invasive Markers for Predicting Significant Fibrosis in Patients with Chronic Liver Disease

Usefulness of Non-invasive Markers for Predicting Significant Fibrosis in Patients with Chronic Liver Disease J Korean Med Sci 21; 25: 67-74 ISSN 111-8934 DOI: 1.3346/jkms.21.25.1.67 Usefulness of Non-invasive Markers for Predicting Significant Fibrosis in Patients with Chronic Liver Disease The purpose of this

More information

/ FIB4 Index , simple steatosis. FIB4 Index. FIB4 Index. FIB4 Index FIB4 Index. Sterling FIB4 Index. FIB4 Index AST AST ALT

/ FIB4 Index , simple steatosis. FIB4 Index. FIB4 Index. FIB4 Index FIB4 Index. Sterling FIB4 Index. FIB4 Index AST AST ALT 原 著 29 34-41, 2014 FIB4 Index 1 1 1 1 2 1 1 FIB4 Index FIB4 Index cut off 2.67 2.67 12,059 FIB4 IndexFIB4 Index 2.67 / FIB4 Index AST ALT FIB4 Index 2.67 161 1.3% FIB4 Index 5 FIB4 Index 1.1 5 1.6 FIB4

More information

Functional liver imaging Bernard Van Beers

Functional liver imaging Bernard Van Beers Functional liver imaging Bernard Van Beers Department of Radiology Beaujon University Hospital Paris Nord Laboratory of Imaging biomarkers UMR 1149 Inserm - University Paris Diderot France Functional imaging

More information

CLINICAL STUDIES. Liver International ISSN

CLINICAL STUDIES. Liver International ISSN Liver International ISSN 1478-3223 CLINICAL STUDIES Biochemical and biophysical assessment of MTX-induced liver brosis in psoriasis patients: predicts the presence and Fibroscan s predicts the absence

More information

JPGN Journal of Pediatric Gastroenterology and Nutrition Publish Ahead of Print

JPGN Journal of Pediatric Gastroenterology and Nutrition Publish Ahead of Print JPGN Journal of Pediatric Gastroenterology and Nutrition Publish Ahead of Print DOI : 10.1097/MPG.0000000000000489 Points to be considered when Applying FibroScan S Probe for Children with Biliary Atresia

More information

1. Introduction. Correspondence should be addressed to Daniela Cabibi;

1. Introduction. Correspondence should be addressed to Daniela Cabibi; Analytical Cellular Pathology Volume 2015, Article ID 431750, 7 pages http://dx.doi.org/10.1155/2015/431750 Research Article Comparison of Histochemical Stainings in Evaluation of Liver Fibrosis and Correlation

More information

Acoustic radiation force impulse elastography in distinguishing hepatic haemangiomata from metastases: preliminary observations

Acoustic radiation force impulse elastography in distinguishing hepatic haemangiomata from metastases: preliminary observations The British Journal of Radiology, 84 (2011), 939 943 SHORT COMMUNICATION Acoustic radiation force impulse elastography in distinguishing hepatic haemangiomata from metastases: preliminary observations

More information

Research Elastography: Liver

Research Elastography: Liver Research Elastography: Liver Giovanna Ferraioli EFSUMB Ultrasound Learning Center Ultrasound Unit - Infectious Diseases Dept. Fondazione IRCCS Policlinico S. Matteo Medical School University of Pavia,

More information

DIFFUSION MRI OF FOCAL LIVER LESIONS

DIFFUSION MRI OF FOCAL LIVER LESIONS ORIGINAL ARTICLE DIFFUSION MRI OF FOCAL LIVER LESIONS Iman Abbas Hosny Department of Radiodiagnosis, Faculty of Medicine, Cairo University, Cairo, Egypt. : 01-07 ABSTRACT OBJECTIVE: To evaluate the diagnostic

More information

Abdominal applications of DWI

Abdominal applications of DWI Postgraduate course, SPR San Antonio (Texas), May 14-15, 2013 Abdominal applications of DWI Rutger A.J. Nievelstein Wilhelmina Children s s Hospital, Utrecht (NL) Outline What is DWI? How to perform? Challenges

More information

Assessment of Liver Fibrosis and Cirrhosis by Aspartate Aminotransferase-to-Platelet Ratio Index in Children With Biliary Atresia

Assessment of Liver Fibrosis and Cirrhosis by Aspartate Aminotransferase-to-Platelet Ratio Index in Children With Biliary Atresia ORIGINAL ARTICLE: HEPATOLOGY AND NUTRITION Assessment of Liver Fibrosis and Cirrhosis by Aspartate Aminotransferase-to-Platelet Ratio Index in Children With Biliary Atresia Sang Yong Kim, y Jae Yeon Seok,

More information

Diffusion-Weighted Imaging of Prostate Cancer

Diffusion-Weighted Imaging of Prostate Cancer ORIGINAL ARTICLE Diffusion-Weighted Imaging of Prostate Cancer Ryota Shimofusa, MD,* Hajime Fujimoto, MD, Hajime Akamata, MD, Ken Motoori, MD,* Seiji Yamamoto, MD,* Takuya Ueda, MD,* and Hisao Ito, MD*

More information

ABSTRACT INTRODUCTION. Jing-Hua Liu 1, Yu Zou 1, Wei Chang 2, Jun Wu 3, Yu Zou 4, Yu-Chen Xie 5, Yong-Ping Lu 6 and Jia Wei 1 *

ABSTRACT INTRODUCTION. Jing-Hua Liu 1, Yu Zou 1, Wei Chang 2, Jun Wu 3, Yu Zou 4, Yu-Chen Xie 5, Yong-Ping Lu 6 and Jia Wei 1 * REVISTA DE INVESTIGACIÓN CLÍNICA Contents available at PubMed www.clinicalandtranslationalinvestigation.com PERMANYER Rev Inves Clin. 2017;69:254-261 ORIGINAL ARTICLE Assessment of Liver Fibrosis Using

More information

Management of Hepatitis C in Primary Care BABAFEMI ONABANJO, MD & BEN ALFRED, FNP UMASS FAMILY HEALTH CENTER WORCESTER

Management of Hepatitis C in Primary Care BABAFEMI ONABANJO, MD & BEN ALFRED, FNP UMASS FAMILY HEALTH CENTER WORCESTER Management of Hepatitis C in Primary Care BABAFEMI ONABANJO, MD & BEN ALFRED, FNP UMASS FAMILY HEALTH CENTER WORCESTER Objective Epidemiology Screening criteria Appropriate work up Treatment Guidelines

More information

EXPERIMENTAL AND THERAPEUTIC MEDICINE 8: , 2014

EXPERIMENTAL AND THERAPEUTIC MEDICINE 8: , 2014 642 Value of hepatic diffusion weighted magnetic resonance imaging in evaluating liver fibrosis following transarterial chemoembolization with low doses of chemotherapy HONG LI, NA LI, QIN XIANG and YAN

More information

Transient elastography: a new surrogate marker of liver fibrosis influenced by major changes of transaminases

Transient elastography: a new surrogate marker of liver fibrosis influenced by major changes of transaminases Journal of Viral Hepatitis, 2007, 14, 360 369 doi:10.1111/j.1365-2893.2006.00811.x Transient elastography: a new surrogate marker of liver fibrosis influenced by major changes of transaminases B. Coco,

More information

Evaluation of liver and spleen stiffness using a ultrasound guided method: Accuracy of ARFI(R) measurements in liver disease patients

Evaluation of liver and spleen stiffness using a ultrasound guided method: Accuracy of ARFI(R) measurements in liver disease patients Evaluation of liver and spleen stiffness using a ultrasound guided method: Accuracy of ARFI(R) measurements in liver disease patients Poster No.: C-3242 Congress: ECR 2010 Type: Topic: Authors: Keywords:

More information

DETECTION AND STAGING OF LIVER FIBROSIS USING ADDITIVE LOGISTIC MODELS

DETECTION AND STAGING OF LIVER FIBROSIS USING ADDITIVE LOGISTIC MODELS DETECTION AND STAGING OF LIVER FIBROSIS USING ADDITIVE LOGISTIC MODELS Cristian Vicas, Sergiu Nedevschi Technical University Cluj Napoca, 2, Gh. Baritiu St. 400027, Cluj Napoca, Romania {cristian.vicas,

More information

Faculty Disclosure. Objectives. Cirrhosis Management for the Family Physician 18/11/2014

Faculty Disclosure. Objectives. Cirrhosis Management for the Family Physician 18/11/2014 Cirrhosis Management for the Family Physician Mang Ma, MD, FRCP Professor University of Alberta Faculty: Mang Ma Faculty Disclosure Relationships with commercial interests: Advisory Board: Merck, Gilead

More information

RECENT ADVANCES IN CLINICAL MR OF ARTICULAR CARTILAGE

RECENT ADVANCES IN CLINICAL MR OF ARTICULAR CARTILAGE In Practice RECENT ADVANCES IN CLINICAL MR OF ARTICULAR CARTILAGE By Atsuya Watanabe, MD, PhD, Director, Advanced Diagnostic Imaging Center and Associate Professor, Department of Orthopedic Surgery, Teikyo

More information

NON INVASIVE EVALUATION OF DISEASE PROGRESSION IN CHRONIC LIVER DISEASES

NON INVASIVE EVALUATION OF DISEASE PROGRESSION IN CHRONIC LIVER DISEASES Best of EASL -, Ethiopia 29 Sep to 01 Oct, 2016 Inaugural meeting of the Sub Saharan GI-Hepatology Working Group Incorporating Best of AGA and Best of EASL NON INVASIVE EVALUATION OF DISEASE PROGRESSION

More information

FibroScore for the Non-invasive Assessment of Liver Fibrosis in Chronic Viral Hepatitis

FibroScore for the Non-invasive Assessment of Liver Fibrosis in Chronic Viral Hepatitis ORIGINAL ARTICLE FibroScore for the Non-invasive Assessment of Liver Fibrosis in Chronic Viral Hepatitis Shahzad Ashraf 1, Syed Azhar Ahmed 2, Jameel Ahmed 3 and Nadir Ali 4 ABSTRACT Objective: To evaluate

More information

Hepatology for the Nonhepatologist

Hepatology for the Nonhepatologist Hepatology for the Nonhepatologist Kenneth E. Sherman, MD, PhD Gould Professor of Medicine Director, Division of Digestive Diseases University of Cincinnati College of Medicine Cincinnati, Ohio Learning

More information

Transient elastography in chronic liver diseases of other etiologies

Transient elastography in chronic liver diseases of other etiologies 4 Post Meeting A.I.S.F. Unmet Clinical Needs in Hepatology: New and upcoming diagnostic tools" Transient elastography in chronic liver diseases of other etiologies Dr. Vincenza Calvaruso Gastroenterologia

More information

Multianalyte assays with algorithmic analyses are considered investigational for the diagnosis or monitoring of patients with chronic liver disease.

Multianalyte assays with algorithmic analyses are considered investigational for the diagnosis or monitoring of patients with chronic liver disease. 2.04.41 Multianalyte Assays with Algorithmic Analysis for the Evaluation and Monitoring of Patients with Chronic Liver Disease Section 2.0 Medicine Subsection 2.04 Pathology/Laboratory Effective Date September

More information

Pretreatment assessment of Chronic Hepatitis C and Compensated Cirrhosis and Indications for Therapy

Pretreatment assessment of Chronic Hepatitis C and Compensated Cirrhosis and Indications for Therapy Pretreatment assessment of Chronic Hepatitis C and Compensated Cirrhosis and Indications for Therapy Teerha Piratvisuth MD. Prince of Songkla University Treatment of chronic hepatitis C and response rates

More information

Noninvasive Assessment of Hepatic Fibrosis in Patients with Chronic Hepatitis B Viral Infection Using Magnetic Resonance Elastography

Noninvasive Assessment of Hepatic Fibrosis in Patients with Chronic Hepatitis B Viral Infection Using Magnetic Resonance Elastography Original Article Gastrointestinal Imaging http://dx.doi.org/10.3348/kjr.2014.15.2.210 pissn 1229-6929 eissn 2005-8330 Korean J Radiol 2014;15(2):210-217 Noninvasive Assessment of Hepatic Fibrosis in Patients

More information

Comparison of transient elastography to Doppler indices in prediction of hepatitis C induced liver fibrosis and cirrhosis

Comparison of transient elastography to Doppler indices in prediction of hepatitis C induced liver fibrosis and cirrhosis The Egyptian Journal of Radiology and Nuclear Medicine (2011) 42, 111 117 Egyptian Society of Radiology and Nuclear Medicine The Egyptian Journal of Radiology and Nuclear Medicine www.elsevier.com/locate/ejrnm

More information

1264 BOURSIER ET AL CLINICAL GASTROENTEROLOGY AND HEPATOLOGY Vol. 6, No. 11 Table 1. Study Design: Assignment of Judges According to Patient and Obser

1264 BOURSIER ET AL CLINICAL GASTROENTEROLOGY AND HEPATOLOGY Vol. 6, No. 11 Table 1. Study Design: Assignment of Judges According to Patient and Obser CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2008;6:1263 1269 Reproducibility of Liver Stiffness Measurement by Ultrasonographic Elastometry JÉRÔME BOURSIER,*, ANSELME KONATÉ,*, GABRIELLA GOREA,* STÉPHANE

More information

Laboratory Tests and Diagnostic Procedures in Liver Disease: Adventures in Liverland

Laboratory Tests and Diagnostic Procedures in Liver Disease: Adventures in Liverland Laboratory Tests and Diagnostic Procedures in Liver Disease: Adventures in Liverland Sanjiv Chopra, MD, MACP Professor of Medicine Harvard Medical School Editor In Chief Hepatology Section Up To Date Serum

More information

Pretreatment Evaluation

Pretreatment Evaluation Pretreatment Evaluation Disclosures Research supported by Gilead Sciences Inc.: Site investigator for HIV/HCV SWITCH Registry Study Key personnel for FOCUS HCV Screening Program through Vanderbilt University

More information

Supplementary appendix

Supplementary appendix Supplementary appendix This appendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors. Supplement to: Harris R, Harman DJ, Card TR, Aithal GP, Guha

More information

Evaluation of Liver Fibrosis using ShearWave Elastography on Aixplorer

Evaluation of Liver Fibrosis using ShearWave Elastography on Aixplorer Evaluation of Liver Fibrosis using ShearWave Elastography on Aixplorer SSID02892-01 November 2012 Evaluation of Liver Fibrosis using SWE on Aixplorer Introduction From a clinical standpoint, staging liver

More information

Clinical application of 3.0 T proton MR spectroscopy in evaluation of pancreatic diseases

Clinical application of 3.0 T proton MR spectroscopy in evaluation of pancreatic diseases Clinical application of 3.0 T proton MR spectroscopy in evaluation of pancreatic diseases Award: Cum Laude Poster No.: C-1762 Congress: ECR 2012 Type: Scientific Paper Authors: T. Su, E. Jin; Beijing/CN

More information

Non-invasive assessment of liver fibrosis in chronic hepatitis B

Non-invasive assessment of liver fibrosis in chronic hepatitis B Submit a Manuscript: http://www.wjgnet.com/esps/ Help Desk: http://www.wjgnet.com/esps/helpdesk.aspx DOI: 10.3748/wjg.v20.i40.14568 World J Gastroenterol 2014 October 28; 20(40): 14568-14580 ISSN 1007-9327

More information

Clinical Policy Title: Liver elastography

Clinical Policy Title: Liver elastography Clinical Policy Title: Liver elastography Clinical Policy Number: CCP.1118 Effective Date: October 1, 2014 Initial Review Date: June 18, 2014 Most Recent Review Date: August 7, 2018 Next Review Date: August

More information

An Accurate Definition of the Status of Inactive Hepatitis B Virus Carrier by a Combination of Biomarkers (FibroTest-ActiTest) and Viral Load

An Accurate Definition of the Status of Inactive Hepatitis B Virus Carrier by a Combination of Biomarkers (FibroTest-ActiTest) and Viral Load An Accurate Definition of the Status of Inactive Hepatitis B Virus Carrier by a Combination of Biomarkers (FibroTest-ActiTest) and Viral Load Yen Ngo 1, Yves Benhamou 1, Vincent Thibault 2, Patrick Ingiliz

More information